Class information for:
Level 1: HER2//HER 2 NEU//TOP2A

Basic class information
Class id #P Avg. number of
references		 Database coverage
of references
6321 1500 35.1 86%


Bar chart of Publication_year

Last years might be incomplete

Hierarchy of classes
The table includes all classes above and classes immediately below the current class.


Cluster id Level Cluster label #P
0 4 BIOCHEMISTRY & MOLECULAR BIOLOGY//CELL BIOLOGY//ONCOLOGY 4064930
317 3       HER2//TRASTUZUMAB//CHRONIC MYELOID LEUKEMIA 39408
652 2             HER2//TRASTUZUMAB//HER 2 NEU 13568
6321 1                   HER2//HER 2 NEU//TOP2A 1500

Terms with highest relevance score


rank Term termType Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class
1 HER2 authKW 896839 23% 13% 340
2 HER 2 NEU authKW 512429 12% 14% 179
3 TOP2A authKW 351170 2% 51% 34
4 CHROMOGENIC IN SITU HYBRIDIZATION authKW 277243 3% 36% 38
5 CISH authKW 265224 2% 37% 35
6 HER2 TESTING authKW 222658 1% 58% 19
7 POLYSOMY 17 authKW 214997 1% 81% 13
8 HER2 GENE authKW 212730 1% 58% 18
9 HERCEPTEST authKW 208169 1% 68% 15
10 HER 2 authKW 199485 5% 12% 81

Web of Science journal categories


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class
1 Pathology 30771 40% 0% 605
2 Oncology 13048 48% 0% 724
3 Medical Laboratory Technology 4169 9% 0% 134
4 Anatomy & Morphology 937 4% 0% 54
5 Medicine, Research & Experimental 199 5% 0% 82
6 Obstetrics & Gynecology 175 4% 0% 61
7 Cell Biology 142 7% 0% 106
8 Medicine, General & Internal 22 4% 0% 54
9 Biotechnology & Applied Microbiology 4 2% 0% 35
10 Genetics & Heredity 3 2% 0% 32

Address terms


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class
1 ENDOCRINE CANC GRP 129599 1% 29% 22
2 UNITE TRANSFERT CANCEROL CLIN 61066 0% 100% 3
3 UK EXTERNAL QUAL ASSESSMENT EME 54278 0% 67% 4
4 TISSUE TUMOR BANK 45798 0% 75% 3
5 GRP ETUD TEURS PRONOST IMMUNOHISTOCHIM CANC SE 40710 0% 100% 2
6 TRANSLAT SECT 36175 1% 22% 8
7 CLIN PATHOL L11 30530 0% 50% 3
8 TRANSFORMAT PATHOL 30530 0% 50% 3
9 HELLEN FDN CANC 28412 1% 16% 9
10 PATHOL 27925 51% 0% 764

Journals


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class
1 APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY 37014 3% 4% 52
2 BREAST CANCER RESEARCH AND TREATMENT 16603 5% 1% 77
3 AMERICAN JOURNAL OF CLINICAL PATHOLOGY 16130 5% 1% 82
4 MODERN PATHOLOGY 10581 3% 1% 50
5 JOURNAL OF CLINICAL PATHOLOGY 6770 4% 1% 54
6 BREAST CANCER 6377 1% 2% 14
7 BREAST CANCER RESEARCH 6296 2% 1% 26
8 BREAST 4415 2% 1% 23
9 CELLULAR ONCOLOGY 4293 1% 2% 10
10 HISTOPATHOLOGY 3694 2% 1% 32

Author Key Words


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class		 LCSH search Wikipedia search
1 HER2 896839 23% 13% 340 Search HER2 Search HER2
2 HER 2 NEU 512429 12% 14% 179 Search HER+2+NEU Search HER+2+NEU
3 TOP2A 351170 2% 51% 34 Search TOP2A Search TOP2A
4 CHROMOGENIC IN SITU HYBRIDIZATION 277243 3% 36% 38 Search CHROMOGENIC+IN+SITU+HYBRIDIZATION Search CHROMOGENIC+IN+SITU+HYBRIDIZATION
5 CISH 265224 2% 37% 35 Search CISH Search CISH
6 HER2 TESTING 222658 1% 58% 19 Search HER2+TESTING Search HER2+TESTING
7 POLYSOMY 17 214997 1% 81% 13 Search POLYSOMY+17 Search POLYSOMY+17
8 HER2 GENE 212730 1% 58% 18 Search HER2+GENE Search HER2+GENE
9 HERCEPTEST 208169 1% 68% 15 Search HERCEPTEST Search HERCEPTEST
10 HER 2 199485 5% 12% 81 Search HER+2 Search HER+2

Core articles
The table includes core articles in the class. The following variables is taken into account for the relevance score of an article in a cluster c:
(1) Number of references referring to publications in the class.
(2) Share of total number of active references referring to publications in the class.
(3) Age of the article. New articles get higher score than old articles.
(4) Citation rate, normalized to year.


Rank Reference # ref. in
cl.		 Shr. of ref. in
cl.		 Citations
1 WOLFF, AC , HAMMOND, MEH , HICKS, DG , DOWSETT, M , MCSHANE, LM , ALLISON, KH , ALLRED, DC , BARTLETT, JMS , BILOUS, M , FITZGIBBONS, P , ET AL (2013) RECOMMENDATIONS FOR HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 TESTING IN BREAST CANCER: AMERICAN SOCIETY OF CLINICAL ONCOLOGY/COLLEGE OF AMERICAN PATHOLOGISTS CLINICAL PRACTICE GUIDELINE UPDATE.JOURNAL OF CLINICAL ONCOLOGY. VOL. 31. ISSUE 31. P. 3997-+ 103 76% 644
2 WOLFF, AC , HAMMOND, MEH , HICKS, DG , DOWSETT, M , MCSHANE, LM , ALLISON, KH , ALLRED, DC , BARTLETT, JMS , BILOUS, M , FITZGIBBONS, P , ET AL (2014) RECOMMENDATIONS FOR HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 TESTING IN BREAST CANCER AMERICAN SOCIETY OF CLINICAL ONCOLOGY/COLLEGE OF AMERICAN PATHOLOGISTS CLINICAL PRACTICE GUIDELINE UPDATE.ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE. VOL. 138. ISSUE 2. P. 241 -256 104 76% 160
3 WOLFF, AC , HAMMOND, MEH , SCHWARTZ, JN , HAGERTY, KL , ALLRED, DC , COTE, RJ , DOWSETT, M , FITZGIBBONS, PL , HANNA, WM , LANGER, A , ET AL (2007) AMERICAN SOCIETY OF CLINICAL ONCOLOGY/COLLEGE OF AMERICAN PATHOLOGISTS GUIDELINE RECOMMENDATIONS FOR HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 TESTING IN BREAST CANCER.JOURNAL OF CLINICAL ONCOLOGY. VOL. 25. ISSUE 1. P. 118-145 45 73% 1843
4 HANNA, WM , RUSCHOFF, J , BILOUS, M , COUDRY, RA , DOWSETT, M , OSAMURA, RY , PENAULT-LLORCA, F , VAN DE VIJVER, M , VIALE, G , (2014) HER2 IN SITU HYBRIDIZATION IN BREAST CANCER: CLINICAL IMPLICATIONS OF POLYSOMY 17 AND GENETIC HETEROGENEITY.MODERN PATHOLOGY. VOL. 27. ISSUE 1. P. 4-18 59 79% 63
5 FURRER, D , SANSCHAGRIN, F , JACOB, S , DIORIO, C , (2015) ADVANTAGES AND DISADVANTAGES OF TECHNOLOGIES FOR HER2 TESTING IN BREAST CANCER SPECIMENS.AMERICAN JOURNAL OF CLINICAL PATHOLOGY. VOL. 144. ISSUE 5. P. 686 -703 99 66% 0
6 ROSA, FE , SANTOS, RM , ROGATTO, SR , DOMINGUES, MAC , (2013) CHROMOGENIC IN SITU HYBRIDIZATION COMPARED WITH OTHER APPROACHES TO EVALUATE HER2/NEU STATUS IN BREAST CARCINOMAS.BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH. VOL. 46. ISSUE 3. P. 207-216 67 89% 4
7 SANGUEDOLCE, F , BUFO, P , (2015) HER2 ASSESSMENT BY SILVER IN SITU HYBRIDIZATION: WHERE ARE WE NOW?.EXPERT REVIEW OF MOLECULAR DIAGNOSTICS. VOL. 15. ISSUE 3. P. 385 -398 100 58% 0
8 WOLFF, AC , HAMMOND, MEH , SCHWARTZ, JN , HAGERTY, KL , ALLRED, DC , COTE, RJ , DOWSETT, M , FITZGIBBONS, PL , HANNA, WM , LANGER, A , ET AL (2007) AMERICAN SOCIETY OF CLINICAL ONCOLOGY/COLLEGE OF AMERICAN PATHOLOGISTS GUIDELINE RECOMMENDATIONS FOR HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 TESTING IN BREAST CANCER.ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE. VOL. 131. ISSUE 1. P. 18-43 45 73% 744
9 PATHMANATHAN, N , BILOUS, AM , (2012) HER2 TESTING IN BREAST CANCER: AN OVERVIEW OF CURRENT TECHNIQUES AND RECENT DEVELOPMENTS.PATHOLOGY. VOL. 44. ISSUE 7. P. 587-595 72 81% 5
10 LEE, JA , SHAHEEN, M , WALKE, T , DALY, M , (2011) CLINICAL AND HEALTH ECONOMIC OUTCOMES OF ALTERNATIVE HER2 TEST STRATEGIES FOR GUIDING ADJUVANT TRASTUZUMAB THERAPY.EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH. VOL. 11. ISSUE 3. P. 325 -341 59 86% 9

Classes with closest relation at Level 1


Rank Class id link
1 2563 TRASTUZUMAB//LAPATINIB//PERTUZUMAB
2 5180 C ERBB 2//HER 2 NEU//P185
3 13462 HER2//GASTRIC CANCER//HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2
4 19156 TISSUE MICROARRAY//MULTITISSUE BLOCK//PARAFFIN TISSUE CORE BIOPSIES
5 853 TRIPLE NEGATIVE BREAST CANCER//TRIPLE NEGATIVE//ONCOTYPE DX
6 3946 PROGESTERONE RECEPTOR//ESTROGEN RECEPTOR//ER ICA
7 3339 NEOADJUVANT CHEMOTHERAPY//LOCALLY ADVANCED BREAST CANCER//PATHOLOGIC COMPLETE RESPONSE
8 13947 P53//AREA BIOPATOL//BCL 2
9 12433 EI24//CLIN BREAST CARE PROJECT//LOSS OF HETEROZYGOSITY
10 35026 M1B PROSTATE CANCER//BIOMARKER EPIDERMAL GROWTH FACTOR RECEPTOR EGFR//C ERB B 2 NEU GENE

Go to start page